Navigation Links
RELAX-AHF: Poor diuretic response associated with worse clinical outcomes
Date:5/17/2014

Athens, 17 May 2014: Poor diuretic response is associated with worse in-hospital and post-discharge clinical outcomes, results of the RELAX-AHF trial reveal. The study also found that serelaxin has a neutral effect on diuretic response.

These novel data from the RELAX-AHF trial were presented by lead author Professor Adriaan A. Voors at the Heart Failure Congress 2014, held 17-20 May in Athens, Greece. The Congress is the main annual meeting of the Heart Failure Association of the European Society of Cardiology.

RELAX-AHF was a double blind, placebo-controlled trial of 1161 patients admitted to hospital with acute heart failure. Patients were randomised to receive 48-hour infusions of placebo or serelaxin (30g/kg per day) within 16 hours from presentation. Primary analysis of the study showed that serelaxin reduced dyspnoea and decreased 180 day mortality.1

The current substudy, presented for the first time today, had two aims. The first was to confirm preliminary findings of the PROTECT trial, which found that poor diuretic response is a serious clinical problem.2 The second was to investigate whether the beneficial effects of serelaxin discovered in the primary analysis were related to improvement of the diuretic response.

Diuretic response was defined as kilograms of weight loss per 40mg of the loop diuretic furosemide. Professor Voors said: "Congestion is the main problem in patients with acute decompensated heart failure and we give them loop diuretics to get rid of the excess fluid. Patients who respond to the loop diuretic have diuresis and lose weight. But a substantial proportion do not respond to the diuretic, do not diurese and do not lose weight."

He added: "Diuretic response could be measured by urinary output but when patients no longer need a catheter it is difficult to capture how much fluid they have lost. We therefore used weight loss as a more objective and reliable measurement of diuretic response. The more weight patients lost per mg of furosemide given, the better their diuretic response."

The study found that diuretic response was an important clinical problem, confirming preliminary results from the PROTECT trial. Patients with a poor diuretic response had less dyspnoea relief (p=0.0001) and a higher risk of cardiovascular death or rehospitalisation for heart failure or renal failure through day 60 (p<0.004). Poor diuretic response was not associated with increased 180-day cardiovascular mortality (p=0.546).

Professor Voors said: "The most important message from this substudy is that if patients are hospitalised for acute heart failure and do not respond well to their diuretic then they are in trouble. Their recovery in hospital is likely to be worse and when they are sent home there is a good chance that they will be rehospitalised again or even die."

The next question was whether serelaxin influenced patients' response to diuretics. The researchers found that serelaxin had no effect on diuretic response. Patients in the serelaxin group improved clinically and were given fewer diuretics but they lost less weight than the placebo group.

Professor Voors said: "Patients felt better with serelaxin and so physicians gave them less diuretics. But these patients did not diurese more, so the overall effect of serelaxin on diuretic response was neutral."

He added: "We will continue to look for the mechanisms by which serelaxin exerts its positive effects. The current study shows that the beneficial effects of serelaxin are not through improvement of diuretic response. We have already shown that serelaxin prevents the organ damage that occurs during an episode of acute heart failure3 and we will continue to investigate other modes of action."

Professor Voors concluded: "The major finding from this substudy of the RELAX-AHF trial is that diuretic resistance is a clinical problem that leads to worse in-hospital and early post-discharge clinical outcomes in patients with acute heart failure. More insights are needed into the problem of poor diuretic response so that better therapies can be found to improve the diuretic response and improve clinical outcomes."


'/>"/>

Contact: Jacqueline Partarrieu
press@escardio.org
33-622-834-576
European Society of Cardiology
Source:Eurekalert

Related medicine news :

1. Black patients with hypertension not prescribed diuretics enough
2. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
3. Response to First Treatment May Predict Epilepsys Course
4. Genetic predictor of breast cancer response to chemotherapy
5. Researchers discover how to overcome poor response to radiotherapy caused by low haemoglobin levels
6. A*STAR scientists discover switch to boost anti-viral response to fight infectious diseases
7. Molecular subtypes and genetic alterations may determine response to lung cancer therapy
8. Babies susceptibility to colds linked to immune response at birth
9. Biomarker predicts response to cancer treatment
10. Baseline characteristics of children with mild persistent asthma predict response to ICS
11. Smoking negatively affects response to anti-TNF treatment in patients with rheumatoid arthritis
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/24/2017)... Prior Lake MN (PRWEB) , ... February 24, ... ... the launch of its newly designed TaskMate Go. Core benefits and advantages built ... grain finish and a stylish, functional look and feel. Ability to gain the ...
(Date:2/24/2017)... (PRWEB) , ... February 24, 2017 , ... An in-depth ... at the University of Pittsburgh points to eight genes that may explain why susceptibility ... according to the results of a study published today in the journal npj Schizophrenia. ...
(Date:2/24/2017)... , ... February 24, 2017 , ... ... hearing disabilities, it is so critically important that we all are aware of ... is why Mediaplanet is proud to announce the launch of its newest edition ...
(Date:2/24/2017)... San Diego, CA (PRWEB) , ... February 24, 2017 , ... ... announce its 2017 national conference convening academic faculty engaged in or interested in palliative ... Education and Research,” will be held in North County San Diego on Sept. ...
(Date:2/24/2017)... ... February 24, 2017 , ... The Radiology Business Management Association will ... at the annual Building Better Radiology Marketing Programs conference, held this year ... Worth, Texas. Nine awards are given out in five categories. They are:, ...
Breaking Medicine News(10 mins):
(Date:2/24/2017)... , Feb. 24, 2017  Xynomic Pharmaceuticals, Inc., an ... that it has acquired exclusive worldwide rights to ... innovative HDAC inhibitor targeting hematological and solid tumors. ... Phase 1 and 2 clinical trials of Abexinostat ... have already been completed, demonstrating that Abexinostat ...
(Date:2/23/2017)... 23, 2017 Visiomed, the French leader ... 1997, is changing the landscape of healthcare with ... with pro-active, custom-made solutions. Recognizing the rising demand ... affordable healthcare without walls, Visiomed has launched BewellConnect, ... with healthcare professionals that is empowering the lives ...
(Date:2/23/2017)... 2017  Genesis Healthcare Services has merged with Hospice ... by Bill Monast , President and CEO of ... Nathan Feltman , executives with Home Health Depot, Inc., ... This acquisition helps Hospice Cloud maintain its ... durable medical equipment (DME) solutions for the hospice industry. ...
Breaking Medicine Technology: